Bloemers

Hugo Bloemers, Whitley Bay GB

Patent application number	Description	Published
20100183810	STRAY COATING PREVENTION DEVICE, COATING CHAMBER DEVICE FOR COATING SUBSTRATES, AND METHOD OF COATING - A stray coating prevention device adapted for a coating chamber for coating substrates, said coating chamber including a coating device for dispensing coating material into the coating chamber; a substrate support adapted to support one or more substrates on a support plane, the substrates each having a backside, the support plane dividing the coating chamber into a rear part and a front part of the coating chamber, and the coating device being located in the front part of the coating chamber; wherein the stray coating prevention device comprises a plurality of adsorption traps, the adsorption traps being provided at a surface of the rear part of the coating chamber.	07-22-2010

Patent application number	Description	Published
20100093680	USE OF 3-ALPHA-ANDROSTANEDIOL, OPTIONALLY IN COMBINATION WITH A 5-HT1A AGONIST, IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a 5-HT1A agonist. Optionally, said 3-alpha-androstanediol and said 5HT1	04-15-2010
20100152145	USE OF 3-ALPHA-ANDROSTANEDIOL, OPTIONALLY IN COMBINATION WITH A PDE5 INHIBITOR, IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5 phosphodiesterase (PDE5) inhibitor.	06-17-2010
20100160270	USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION - The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.	06-24-2010

Patent application number	Description	Published
20090306026	Pharmaceutical Formulations and Uses Thereof in the Treatment of Female Sexual Dysfunction - The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analogue thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.	12-10-2009